Hansa Biopharma
Tilbage til tagliste | 132490 | Hansa Biopharma reports positive efficacy and safety results | 27/5 2026 05:24 | exitnu | 3  |
| Hansa Biopharma reports positive efficacy and safety results from Idefirix[®] European post authorization study in kidney transplantation: https://www.hansabiopharma.com/media/press-releases/2.. | ||||
| 132371 | Hansa Biopharma enters into €115 million licensing ... | 19/5 2026 05:36 | exitnu | 4 |
| Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA • The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region • Significantly enhances Hansa's financial position, | ||||
| 132059 | Hansa Biopharma Report First Quarter 2026 Financial Results | 23/4 2026 05:11 | exitnu | 1 |
| Hansa Biopharma Report First Quarter 2026 Financial Results · PDUFA target date set for December 19 by the FDA · Runway significantly extended .. Financial Performance First‑quarter Revenue totalled 34.6 MSEK compared to 66.3 MSEK in Q1 in 2025. IDEFIRIX product sales reached 33.9 MSEK, compare | ||||
| 131656 | Hansa Biopharma USD 30 million convertible note financing | 20/3 2026 07:36 | exitnu | 1 |
| Hansa Biopharma announces a USD 30 million convertible note financing https://www.hansabiopharma.com/media/press-releases/2.. Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) | ||||
| 131199 | Hansa Biopharma's BLA for imlifidase accepted by the FDA | 19/2 2026 07:11 | exitnu | 0 |
| Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA 18 Feb 2026, 19:53 Regulatory information Lund, Sweden, 18 February 2026. Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biolog | ||||
| 131098 | Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 | 11/2 2026 06:21 | exitnu | 2 |
| Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results 11 Feb 2026, 07:00 Regulatory information · Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. · Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney trans | ||||
| 130439 | Hansa Biopharma Submits BLA to FDA | 19/12 2025 19:38 | exitnu | 3 |
| Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation 19 Dec 2025, 20:35 Regulatory information PRESS RELEASE The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzym | ||||
| 129273 | Hansa Biopharma Reports Third Quarter and Interim .. | 30/10 2025 06:18 | exitnu | 2 |
| Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results • Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. • First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allo | ||||
| 127247 | Hansa Biopharma Reports Second Quarter and Interim .. | 17/7 2025 05:04 | exitnu | 1 |
| Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results https://news.cision.com/hansa-biopharma-ab/r/hansa-bi.. | ||||
| 119911 | Hansa Biopharma interim report January-March 2024 | 18/4 2024 05:07 | exitnu | 3 |
| Hansa Biopharma interim report January-March 2024 https://www.hansabiopharma.com/media/press-releases/2.. • Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease • Cash runway extended into 2026 • Evan Ballantyne | ||||
| 119808 | Hansa Biopharma - Directed Share Issue of SEK 372 million | 12/4 2024 06:12 | exitnu | 3 |
| Hansa Biopharma AB: Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million) https://www.hansabiopharma.com/media/press-releases/2.. | ||||
| 118472 | Hansa Biopharma Year-end report January-December 2023 | 2/2 2024 07:27 | exitnu | 0 |
| Hansa Biopharma Year-end report January-December 2023: · Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain · Encouraging results from first-in-human trial of HNSA-5487 · Initiation of phase 1b tria | ||||
| 117815 | Hansa Biopharma provides update | 6/1 2024 14:41 | exitnu | 8 |
| Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in | ||||
| 112327 | Pharma og biotek-opdatering UGE 17 | 27/4 2023 13:38 | ProInvestorNEWS | 8 |
| Demant ' GN Store Nord ' Novo Nordisk ' Genmab ' Zealand Pharma ' Hansa Biopharma Helge Larsen gennemgår det sidste nye om virksomhederne inden for pharma og biotek ud fra den kvalificerede debat og chat på ProInvestor. https://www.youtube.com/watch?v=CjSLNdG5qiQ | ||||
| 108242 | Ugekommentar #69 Julehumør på aktiemarkedet | 1/12 2022 13:40 | ProInvestorNEWS | 5 |
| En tale onsdag aften fra FED's chef Jerome Powell har afspejlet sig positivt på aktiemarkederne. Genmab, Novo Nordisk, Zealand Pharma, Hansa Biopharma og Anavex er bl.a. de selskaber, som Helge Larsen tager et kig på i denne ugekommentar. Som altid er ingen af de nævnte selskaber købsanbefalinger | ||||
| 106987 | Hansa Biopharma - Oversigt over analytikere og kursmål | 16/10 2022 08:15 | ProInvestorNEWS | 3 |
| Analyst Coverage and Analyst Consensus: https://www.hansabiopharma.com/investors/analysts/ Hansa Biopharma har en betalt digital IR-aftale med ProInvestor.com | ||||
| 104621 | Ugekommentar #52 Sommerrally på aktiemarkedet | 21/7 2022 09:57 | Helge Larsen/PI-redaktør | 9 |
| Stigninger på aktiemarkedet i USA smitter af på resten af verden. Fx ser vi gode bankregnskaber og positivt regnskab fra Netflix. Og så er biotek-festen godt i gang med Bavarian Nordic, Genmab, Zealand Pharma og ikke mindst Hansa Biopharma. Men faktorer som inflation, rentestigninger og covid19 lig | ||||
| 104115 | HCW - FIRST TAKE Hansa Biopharma AB | 21/6 2022 12:51 | ProInvestorNEWS | 3 |
| FIRST TAKE Hansa Biopharma AB HNSA.ST: Price: SEK50.35; Market Cap (M): SEK2,239 Rating: Buy; Price Target: SEK223.00 Douglas Tsao NICE Recommendation Is Another Tailwind for Idefirix NICE provides key validation of Idefirix's value. Last week, Hansa announced that the National | ||||
| 93231 | Hansa Biopharma: Transcript fra Q1 | 30/4 2021 10:30 | B.Andersen | 9 |
| Transcript fra Q1. Mange gode spørgsmål og svar på conference call. https://investors.hansabiopharma.com/English/financia.. 10 banker følger nu Hansa Biopharma. Ni analytikere har køb. Konsensus kursmål er i gennemsnit 315. | ||||
| 93036 | Hansa Biopharma interim report Jan-Mar 2021 | 22/4 2021 06:34 | Helge Larsen/PI-redaktør | 6 |
| 8.00 AM CEST / 22-Apr-2021 / Hansa Biopharma AB (STO:HNSA) Hansa Biopharma interim report Jan-Mar 2021 First commercial sales of Idefirix® recorded in Q1; New preclinical collaboration with argenx; Encouraging three-year follow-up data in kidney transplantation Lund, Sweden April 22, 2021 Hansa B | ||||
| 91060 | Hansa Biopharma - Mulige begivenheder indenfor 12-24 mdr. | 16/2 2021 06:12 | Havneholmen | 10 |
| 1. Opstart salg af IDEFIRIX nyretransplantation - melding om første behandlet patient kan komme anytime. Man skal forstå at det er en helt ny type behandling og lægerne skal have god erfaring med brugen af IDEFIRIX inden det helt store salg går i gang. Data er outstanding med sænkning af IGG helt i | ||||
| 87727 | Hansa Biopharma: ABG øger kursmål fra SEK 239 til SEK 404 | 20/10 2020 05:26 | B.Andersen | 12 |
| Prisen på Idefirix (imlifidase) blev i går offentliggjort på lægemiddelstyrelsens hjemmeside i Danmark som det første europæiske land https://medicinpriser.dk/Default.aspx?id=15&vnr=084630 Indkøbsprisen er sat til DKK 2,2 mio eller EUR 297 700. Prisen er baseret på en two-pack med to viraler svaren | ||||
| 87029 | Hansa Bio positiva resultat från fas 2-studien med imlifidas | 24/9 2020 19:21 | Aps invest | 8 |
| STOCKHOLM (Nyhetsbyrån Direkt) Bioteknikbolaget Hansa Biopharma meddelade under torsdagen positiva resultat från fas 2-studien med imlifidase. Det framgår av ett pressmeddelande. Studien visar att imlifidase snabbt eliminerar anti-GBM-antikroppar och att två tredjedelar av patienterna inte behövde | ||||
| 85969 | Hansa Biopharma - Webcast fra Nordea Conference | 19/8 2020 10:57 | B.Andersen | 1 |
| Webcast fra seneste Nordea conference (Aug 13, 2020) 20 min webcast https://streamio.com/api/v1/videos/5f3512566f8d8dd4d8.. | ||||
| 84828 | Hansa Biopharma receives positive CHMP opinion | 25/6 2020 16:07 | Helge Larsen/PI-redaktør | 7 |
| Hansa Biopharma receives positive CHMP opinion for IdefirixTM (imlifidase) for kidney transplant in EU The positive opinion marks an important milestone as the Company prepares its transformation into a commercial stage biopharmaceutical company. Lund, Sweden June 25, 2020. Hansa Biopharma, the l | ||||